Skip to main content

Retinitis Pigmentosa 11

2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

PYC Therapeutics
PYC TherapeuticsAustralia - Nedlands
2 programs
1
1
VP-001Phase 1/21 trial
VP-001Phase 11 trial
Active Trials
NCT06455826Completed6Est. Nov 2025
NCT06852963Recruiting16Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
PYC TherapeuticsVP-001
PYC TherapeuticsVP-001

Clinical Trials (2)

Total enrollment: 22 patients across 2 trials

NCT06852963PYC TherapeuticsVP-001

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Start: Jun 2025Est. completion: Mar 202816 patients
Phase 1/2Recruiting
NCT06455826PYC TherapeuticsVP-001

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Start: Jun 2024Est. completion: Nov 20256 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 22 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.